Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

Table 2 In vivo NKG2D ligand expression in sequential Ewing sarcoma tumour samples

UPN^a	sample type (years after diagnosis)	MICA	ULBP1
1	post-chemotherapy resection-GR^b	n.e.	+
	lung metastasis (2)	++	+
	mediastinal metastasis (3)	++	+
2	pre-treatment biopsy	++	+
	post-chemotherapy resection-GR	+	++
	lung metastasis (5)	+	+/-
	lymph node metastasis (9)	++	n.e.
3	pre-treatment biopsy	+	+
	post-chemotherapy resection-GR	++	+
	lung metastasis (3)	+	++
	lung metastasis (4)	+	n.e.
4	pre-treatment biopsy	+	+
	post-chemotherapy resection-PR^c	++	+
	bone metastasis (1)	++	-
5	pre-treatment biopsy	++	+/-
	post-chemotherapy resection-PR	++	+
	lung metastasis (1)	++	+/-
6	pre-treatment biopsy	++	-
	post-chemotherapy resection-PR	++	+/-
	lung metastasis (0.5)	++	-
	lung metastasis (2.5)	++	+/-
	lung metastasis (3)	++	+/-
	bone metastasis (3)	++	-
7	post-chemotherapy resection-PR	++	+/-
	lung metastasis (1.5)	++	+
	bone metastasis (2.5)	++	+/-
	lung metastasis (4)	++	+
	lung metastasis (4)	++	+/-
	lung metastasis (5)	++	++
	paravertebral metastasis (5)	++	+
8	pre-treatment biopsy	++	+
	post-chemotherapy resection-GR	+	n.e.
	lung metastasis (8)	++	+

^aUPN = unique patient number. ^bGR = good chemotherapy response. ^cPR = poor chemotherapy
response. n.e. = not evaluable.-= absent, +/- = weak, + = moderate, ++ = strong expression.

ISSN: 2045-3329